StreetAlpha.app
Home › Stocks › ANVS

Annovis Bio, Inc. (ANVS)

Healthcare
$0.71
▼ −4.96%
LAST CLOSE · NOV 20

Annovis Bio develops buntanetap, an experimental oral drug for Alzheimer's and Parkinson's disease. It last closed at $0.71 on Nov 20, down 4.96% on the day. The next earnings report for ANVS is expected around Mon, Mar 15, 2027, after the close. For the quarter ended Sep 2026, ANVS reported EPS of -$0.22 on revenue of $0. Over its last 8 reports the stock moved an average of 8.6% the session after earnings. Over the last 12 months ANVS insiders bought $7.1M of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is ANVS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ANVS.

Key Stats

Last 12 months
Results
Revenue
$0
Net income
−$51.7M
EPS (diluted)
−$1.55
Valuation
Market cap
$44.1M
62.0M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$2.8M
At Sep 30
Shareholder equity
−$13.2M
Shares outstanding
62.0M
At Nov 13
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2021: $0$0FY2021FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $0$0FY2024FY2025: $0$0FY2025

From ANVS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Next report
Mar 15
Estimated date · After the close
Reported EPS
-$0.22
Quarter ended Sep 2026
Year ago EPS
-$0.37
Same quarter last year
Revenue
$0
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.42Dec '24Mar 2025: -$0.32Mar '25Jun 2025: -$0.32Jun '25Sep 2025: -$0.37Sep '25Dec 2025: -$0.39Dec '25Mar 2026: -$0.63Mar '26Jun 2026: -$0.40Jun '26Sep 2026: -$0.22Sep '26Latest -$0.22
Revenue by quarter
Dec 2024: $0Dec '24Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Mar 2026: $0Mar '26Jun 2026: $0Jun '26Sep 2026: $0Sep '26Latest $0
How ANVS moved after its last 8 reports
Average move the session after a report ±8.6%
Nov 4, 2026After the close−44.7%
Aug 14, 2026After the close−6.0%
May 15, 2026After the close−0.5%
Mar 16, 2026After the close−3.2%
Nov 12, 2025After the close−5.8%
Aug 12, 2025After the close−2.5%
May 13, 2025After the close−0.6%
Mar 21, 2025After the close+5.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ANVSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ANVS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ANVS

Technical Analysis

ANVS · as of the Nov 20 close · updated each morning
Downtrend

The stock is 28% below its 20 day and 48% below its 50 day average. It is 149% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 39). The nearest support is the Pivot S1 at $0.68, and the nearest resistance the Pivot at $0.73.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 18.0%/day
Key levels
$5.5052 week high+674.6%
$1.77200 day average+149.3%
$1.39100 day average+95.8%
$1.0550 day average+47.9%
$0.95Swing high (Nov 13)+33.8%
$0.9120 day average+28.2%
$0.76Pivot R1+7.0%
$0.73Pivot+2.8%
$0.71Last close
$0.68Pivot S1−4.2%
$0.6252 week low−12.7%
$0.62Swing low (Nov 5)−12.7%
Indicators
RSI (14)38.57Weak, oversold below 30Neutral
MACD-0.09Below its signal lineBearish
Stochastic20.3Middle of its rangeNeutral
ADX (14)18.2No clear trend
Williams %R-85.0Oversold below −80, overbought above −20Oversold
CCI (20)-100.1Oversold below −100, overbought above 100Oversold
Rate of change−15.8%Change over 10 sessionsBearish
ATR (14)$0.13Typical daily range, 18.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ANVS

What happened before

See how ANVS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ANVS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ANVS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ANVSHow many large options trades hit ANVS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ANVS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▲26 buying vs 18 selling
  • ▼Held by funds -5.6 pts
  • ▼Funds holding -1
  • ▼Superinvestors: 0 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding6061−1.6%
In funds' top 1001−100.0%
Held by funds11.9%17.5%−5.6 pts
New / increased8 / 1815 / 17−18.8%
Reduced / sold out8 / 106 / 11+5.9%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ANVS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ANVS Insider Trading

All filings →
Insider trading · 12 months
Insiders are buying
Bought$7.1M6 buys · 1 insider
Sold$00 sales · 0 insiders
Cluster buy: 2 insiders bought $2.5M between Oct 28 and Nov 24.
2025-12 bought $194K2026-04 bought $1.5M2026-05 bought $143K2026-11 bought $5.0MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 6Michael B HoffmanDirectorBuy5,000,000$1.00$5.0M
May 20Michael B HoffmanDirectorBuy76,344$1.87$143K
Apr 2Michael B HoffmanDirectorBuy713,800$2.10$1.5M
Dec 8, 2025Michael B HoffmanDirectorBuy45,000$4.31$194K
Nov 24, 2025Michael B HoffmanDirectorBuy39,200$4.08$160K
Nov 21, 2025Michael B HoffmanDirectorBuy20,000$3.50$70K
Every insider buy and sale for ANVS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ANVS insider trades →

From SEC Form 4 filings by ANVS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANVS is in one of them and how their past ANVS trades turned out.

ANVS in the AI portfolios
Loading…

ANVS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ANVS in an article yet. Here's the latest on the wider market.

ANVS in the news

About Annovis Bio

Annovis Bio is a drug development company focused on neurodegenerative diseases such as Alzheimer's and Parkinson's. Its main product candidate, buntanetap, is an oral small molecule drug designed to lower several harmful proteins linked to nerve cell damage. The company is still in clinical testing and does not yet have an approved product for sale, so its intended customers are patients with these diseases. It is based in Malvern, Pennsylvania.

Headquarters
Malvern, PA